Works matching Peter O'Donnell

Results: 802
    1
    2
    3
    4
    5
    6
    7
    8

    The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans.

    Published in:
    CTS: Clinical & Translational Science, 2019, v. 12, n. 3, p. 209, doi. 10.1111/cts.12608
    By:
    • Friedman, Paula N.;
    • Shaazuddin, Mohammed;
    • Gong, Li;
    • Grossman, Robert L.;
    • Harralson, Arthur F.;
    • Klein, Teri E.;
    • Lee, Norman H.;
    • Miller, Doriane C.;
    • Nutescu, Edith A.;
    • O'Brien, Travis J.;
    • O'Donnell, Peter H.;
    • O'Leary, Kevin J.;
    • Tuck, Matthew;
    • Meltzer, David O.;
    • Perera, Minoli A.
    Publication type:
    Article
    9
    10

    LIGHT ACTIVATION OF ENZYMES.

    Published in:
    Photochemistry & Photobiology, 1980, v. 32, n. 6, p. 841, doi. 10.1111/j.1751-1097.1980.tb04065.x
    By:
    • Hug, Daniel H.;
    • O'Donnell, Peter S.;
    • Hunter, John K.
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    In Reply.

    Published in:
    2022
    By:
    • Lacouture, Mario E;
    • Patel, Anisha B;
    • Rosenberg, Jonathan E;
    • O'Donnell, Peter H
    Publication type:
    Letter to the Editor
    26

    In Reply.

    Published in:
    2022
    By:
    • Lacouture, Mario E;
    • Patel, Anisha B;
    • Rosenberg, Jonathan E;
    • O'Donnell, Peter H
    Publication type:
    Letter to the Editor
    27
    28
    29
    30
    31

    Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.

    Published in:
    Leukemia & Lymphoma, 2010, v. 51, n. 12, p. 2240, doi. 10.3109/10428194.2010.520773
    By:
    • O'Donnell, Peter H.;
    • Artz, Andrew S.;
    • Undevia, Samir D.;
    • Pai, Rish K.;
    • Del Cerro, Paula;
    • Horowitz, Sarah;
    • Godley, Lucy A.;
    • Hart, John;
    • Innocenti, Federico;
    • Larson, Richard A.;
    • Odenike, Olatoyosi M.;
    • Stock, Wendy;
    • Van Besien, Koen
    Publication type:
    Article
    32
    33
    34
    35

    Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group

    Published in:
    Cancer (0008543X), 2013, v. 119, n. 11, p. 1994, doi. 10.1002/cncr.27973
    By:
    • Galsky, Matthew D.;
    • Hendricks, Ryan;
    • Svatek, Robert;
    • Bangs, Rick;
    • Hoffman‐Censits, Jean;
    • Clement, Jessica;
    • Dreicer, Robert;
    • Guancial, Elizabeth;
    • Hahn, Noah;
    • Lerner, Seth P.;
    • O'Donnell, Peter H.;
    • Quale, Diane Zipursky;
    • Siefker‐Radtke, Arlene;
    • Shipley, William;
    • Sonpavde, Guru;
    • Vaena, Daniel;
    • Vinson, Jacob;
    • Rosenberg, Jonathan
    Publication type:
    Article
    36
    37

    Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

    Published in:
    Breast Cancer Research & Treatment, 2020, v. 181, n. 3, p. 623, doi. 10.1007/s10549-020-05603-8
    By:
    • O'Donnell, Peter H.;
    • Trubetskoy, Vassily;
    • Nurhussein-Patterson, Ashley;
    • Hall, Julianne P.;
    • Nath, Aritro;
    • Huo, Dezheng;
    • Fleming, Gini F.;
    • Ingle, James N.;
    • Abramson, Vandana G.;
    • Morrow, P. K.;
    • Storniolo, Anna Maria;
    • Forero, Andres;
    • Van Poznak, Catherine;
    • Liu, Minetta C.;
    • Chang, Jenny C.;
    • Merkel, Douglas E.;
    • Peppercorn, Jeffrey M.;
    • Rugo, Hope S.;
    • Dees, E. Claire;
    • Hahn, Olwen M.
    Publication type:
    Article
    38
    39
    40
    41
    42

    A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.

    Published in:
    BJU International, 2014, v. 113, n. 5b, p. E137, doi. 10.1111/bju.12564
    By:
    • Pond, Gregory R.;
    • Agarwal, Neeraj;
    • Bellmunt, Joaquim;
    • Choueiri, Toni K.;
    • Qu, Angela;
    • Fougeray, Ronan;
    • Vaughn, David;
    • James, Nicholas D.;
    • Salhi, Yacine;
    • Albers, Peter;
    • Niegisch, Günter;
    • Galsky, Matthew D.;
    • Wong, Yu‐Ning;
    • Ko, Yoo‐Joung;
    • Stadler, Walter M.;
    • O'Donnell, Peter H.;
    • Sridhar, Srikala S.;
    • Vogelzang, Nicholas J.;
    • Necchi, Andrea;
    • Di Lorenzo, Giuseppe
    Publication type:
    Article
    43
    44
    45

    Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 1, p. 1, doi. 10.1002/cncr.35601
    By:
    • O'Donnell, Peter H.;
    • Loriot, Yohann;
    • Csoszi, Tibor;
    • Matsubara, Nobuaki;
    • Shin, Sang Joon;
    • Park, Se Hoon;
    • Atduev, Vagif;
    • Gumus, Mahmut;
    • Karaca, Saziye Burcak;
    • Grivas, Petros;
    • de Wit, Ronald;
    • Castellano, Daniel E.;
    • Powles, Thomas;
    • Vuky, Jacqueline;
    • Zhao, Yujie;
    • O'Hara, Karen;
    • Okpara, Chinyere E.;
    • Franco, Sonia;
    • Homet Moreno, Blanca;
    • Żołnierek, Jakub
    Publication type:
    Article
    46
    47

    A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.

    Published in:
    2020
    By:
    • Zhang, Tian;
    • Harrison, Michael R.;
    • O'Donnell, Peter H.;
    • Alva, Ajjai S.;
    • Hahn, Noah M.;
    • Appleman, Leonard J.;
    • Cetnar, Jeremy;
    • Burke, John M.;
    • Fleming, Mark T.;
    • Milowsky, Matthew I.;
    • Mortazavi, Amir;
    • Shore, Neal;
    • Sonpavde, Guru P.;
    • Schmidt, Emmett V.;
    • Bitman, Bojena;
    • Munugalavadla, Veerendra;
    • Izumi, Raquel;
    • Patel, Priti;
    • Staats, Janet;
    • Chan, Cliburn
    Publication type:
    journal article
    48

    Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.

    Published in:
    2020
    By:
    • O'Donnell, Peter H.;
    • Arkenau, Hendrick Tobias;
    • Sridhar, Srikala S.;
    • Ong, Michael;
    • Drakaki, Alexandra;
    • Spira, Alexander I.;
    • Zhang, Jingsong;
    • Gordon, Michael S.;
    • Degboe, Arnold N.;
    • Gupta, Ashok K.;
    • Mukhopadhyay, Pralay;
    • Huang, Wenmei;
    • Abdullah, Shaad E.;
    • Angra, Natasha;
    • Roskos, Lorin K.;
    • Guo, Xiang;
    • Friedlander, Terence
    Publication type:
    journal article
    49

    Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

    Published in:
    2019
    By:
    • Grivas, Petros;
    • Mortazavi, Amir;
    • Picus, Joel;
    • Hahn, Noah M.;
    • Milowsky, Matthew I.;
    • Hart, Lowell L.;
    • Alva, Ajjai;
    • Bellmunt, Joaquim;
    • Pal, Sumanta K.;
    • Bambury, Richard M.;
    • O'Donnell, Peter H.;
    • Gupta, Sumati;
    • Guancial, Elizabeth A.;
    • Sonpavde, Guru P.;
    • Faltaos, Demiana;
    • Potvin, Diane;
    • Christensen, James G.;
    • Chao, Richard C.;
    • Rosenberg, Jonathan E.
    Publication type:
    journal article
    50